98%
921
2 minutes
20
Objective: The costs related to robotic surgery are known to be greater than those associated with laparoscopy. However, the potential for better outcomes of the former could lead to a cost-effectiveness advantage. The aim of this study is therefore to highlight the difference in cost-effectiveness between robotic and laparoscopic rectal resection.
Methods: This is an observational, multicenter, national prospective study (ROBOCOSTES). From 2022, for 1 year, all consecutive patients undergoing minimally invasive rectal resection were included. Quality-adjusted life year and cost data were prospectively collected. The primary aim was to assess the cost-effectiveness of robotic rectal resection and laparoscopic rectal resection . Secondary aims included clinical outcomes and quality of life.
Results: Overall, 182 patients underwent rectal resection (152 anterior and 30 abdominoperineal excisions) at 14 centers, of whom 95 received robotic rectal resection and 87 laparoscopic rectal resection. Robotic rectal resection was associated with lesser blood loss (58.55 ± 51.68 vs 131.68 ± 191.92, P < .001), lower pain score at day 1 (-1.04 visual analog scale, P < .001) and day 7 (-0.81, P < .001) after surgery, and with fewer hospital readmissions (2.1% vs 15%, P = .005) compared with laparoscopic rectal resection. The overall costs of robotic rectal resection (including hospitalization) were 919.66 euros greater compared with laparoscopic rectal resection, but quality-adjusted life years in the robotic rectal resection group were better than laparoscopic approaches to rectal resection both at 30-day (0.8914 vs 0.8139) and 90-day (0.9573 vs 0.8740) follow-up. At a willingness-to-pay threshold of 20,000 and 30,000 euros, there was an 84.38% and 89.36% probability that robotic rectal resection was more cost-effective than laparoscopic rectal resection.
Conclusion: This study showed that robotic rectal resection, even if associated with greater direct costs in the short term, outperforms laparoscopic rectal resection in terms of quality-adjusted life years and should therefore be preferred where available.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.surg.2024.109134 | DOI Listing |
J Robot Surg
September 2025
Department of Oncology, Shengli Oilfield Central Hospital, Dongying, China.
A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT.
View Article and Find Full Text PDFSurg Endosc
September 2025
Department of Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität, Campus Virchow Klinikum, Campus Charité Mitte, Augustenburger Platz 1, 13353, Berlin, Germany.
Introduction: High tie ligation of the inferior mesenteric artery (IMA) is the standard technique in oncological low anterior rectal resection. However, high tie may reduce blood flow to the colon, impairing distal tissue perfusion, anastomotic healing, and potentially causing necrosis. Therefore, a modified high tie technique (MoHiTi) was developed that preserves the arterial arc from the left colic artery via the proximal IMA to the first sigmoidal branch.
View Article and Find Full Text PDFFam Cancer
September 2025
Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Avenue / A30, Cleveland, OH, 44195, USA.
Familial adenomatous polyposis (FAP) is an inherited condition that predisposes individuals to colorectal cancer without preventive treatment. Surgical management typically involves restorative proctocolectomy with an ileal pouch anal anastomosis or colectomy with ileorectal anastomosis. Complete removal of the large intestine and rectum with a permanent stoma may also be required in selected cases.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of General Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Background: Anorectal malignant melanoma (ARMM) is an exceedingly rare and highly aggressive malignancy characterized by low prevalence, high misdiagnosis rates, and frequent recurrence/metastasis.
Case Report: This report details the case of a 51-year-old woman presenting with persistent bright red blood in her stool. Digital rectal examination revealed a firm, spherical mass approximately 4 cm from the anal verge.
Front Oncol
August 2025
Department of Surgical Oncology, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, Guangdong, China.
Microsatellite-stable (MSS) rectal adenocarcinoma remains a therapeutic challenge, particularly in patients with complicating factors such as chronic hepatitis B virus (HBV) infection. Advances in immunotherapy, including immune checkpoint inhibitors (ICIs), have introduced new opportunities to improve the treatment outcomes in this subset, yet their application in HBV-positive cancer patients is less well understood. Here we report the case of a 46-year-old female with MSS locally advanced rectal adenocarcinoma and active HBV infection, successfully treated with cmFOLFOXIRI combined with camrelizumab as neoadjuvant therapy.
View Article and Find Full Text PDF